Back to today’s briefing

Story perspectives

Hims & Hers Faces Setback as FDA Revokes Drug Approval

4/11/2025

25 6

Summary

Story summary

Hims & Hers is grappling with a setback as the FDA pulls its approval for compounded GLP-1 weight-loss drugs, which accounted for 15% of its revenue. In response, CEO Andrew Dudum is shifting focus to traditional weight-loss medications and tailored treatments. Meanwhile, Noom pushes for a "High-Priced Drug List" to enhance access to these vital compounded drugs.

1 of 1

Story summary

Hims & Hers is grappling with a setback as the FDA pulls its approval for compounded GLP-1 weight-loss drugs, which accounted for 15% of its revenue. In response, CEO Andrew Dudum is shifting focus to traditional weight-loss medications and tailored treatments. Meanwhile, Noom pushes for a "High-Priced Drug List" to enhance access to these vital compounded drugs.